Hapvida Participacoes e Investimentos (HAPV3) Q4 2024 earnings summary

Executive summary

• Successfully concluded a major integration cycle, unifying acquired entities and systems by December 2024, positioning for growth in 2025 with a focus on digitalization and network expansion.

• Maintained recovery trajectory with strong cash generation, reduced leverage, margin improvement, and increased investments in network expansion and systems integration.

• Overcame significant operational challenges in 2024, including major floods and a dengue epidemic, while maintaining service quality and controlling claims.

• Achieved historic improvements in customer satisfaction and operational efficiency, with technology and AI-driven initiatives for 2025.

• Health beneficiaries remained stable at 8,869k, while dental beneficiaries declined slightly to 6,932k.

Financial highlights

• Net revenue reached R$28,952.1 million in 2024, up 5.8% year-over-year; 4Q24 net revenue was R$7,472.4 million, up 7.8% from 4Q23.

• Adjusted EBITDA for 2024 was R$3.8 billion, up 34.9% year-over-year; 4Q24 Adjusted EBITDA was R$1,062.6 million, up 19.4% from 4Q23.

• Adjusted net income for 2024 was R$1,836.3 million, up 170% year-over-year; 4Q24 Adjusted Net Income was R$514.7 million.

• Cash MLR improved to 69.2% in 2024 from 71.9% in 2023; 4Q24 Cash MLR was 67.9%.

• Free cash flow for 2024 was R$1,517.6 million, with net cash increasing by R$1,365.1 million to R$9,225.0 million at year-end.

Outlook and guidance

• Positive outlook for 2025, expecting contract readjustments to normalize and continued organic growth in beneficiaries.

• Focus on capturing synergies, digital transformation, and further expansion and upgrading of the healthcare network.

• Anticipates further cost efficiencies and margin improvements as integration and digitalization efforts mature.

• Task force to reduce elective surgery times in São Paulo expected to complete in 2Q25.

• Three new hospitals inaugurated in early 2025 to support network expansion.